Back to top
more

Penumbra (PEN)

(Real Time Quote from BATS)

$240.59 USD

240.59
84,147

-0.15 (-0.06%)

Updated Aug 8, 2025 02:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio

by Zacks Equity Research

Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.

Zacks Equity Research

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.

Zacks Equity Research

Boston Scientific (BSX) Gains From Acquisitions, New Launches

by Zacks Equity Research

Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.

Zacks Equity Research

Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker

by Zacks Equity Research

Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.

Zacks Equity Research

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome

by Zacks Equity Research

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Zacks Equity Research

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Zacks Equity Research

Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs

by Zacks Equity Research

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.

Zacks Equity Research

Zacks.com featured highlights Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment

by Zacks Equity Research

Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment have been highlighted in this Screen of The Week article.

Zacks Equity Research

Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays

by Zacks Equity Research

Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Sail Through Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and AeroVironment (AVAV) are poised to gain.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.

Zacks Equity Research

Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCG

Zacks Equity Research

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.

Zacks Equity Research

Illumina (ILMN) Progresses in Pathogen Genomic Technologies

by Zacks Equity Research

Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.

Zacks Equity Research

Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo

by Zacks Equity Research

Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.

Zacks Equity Research

LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays

by Zacks Equity Research

LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.

Zacks Equity Research

Here's Why Investors Should Retain Henry Schein (HSIC) for Now

by Zacks Equity Research

Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.

Zacks Equity Research

Integra (IART) Builds Advanced R&D Facility in New Jersey

by Zacks Equity Research

Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.

Zacks Equity Research

Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement

by Zacks Equity Research

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Zacks Equity Research

Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays

by Zacks Equity Research

Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.

Zacks Equity Research

Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?

by Zacks Equity Research

Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.

Zacks Equity Research

Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing

by Zacks Equity Research

Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.

Zacks Equity Research

Zacks.com featured highlights include Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk

by Zacks Equity Research

Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk are part of the Zacks Screen of the Week article.